Japan’s Ministry of Health, Labour and Welfare has approved GSK’s depemokimab (Exdensur) as an add-on treatment for certain types of severe asthma.

• Mechanism: Depemokimab is a long-acting biologic that targets interleukin-5 (IL-5), with a dosing schedule of every six months.
• Indication: The approval is specifically for the treatment of severe eosinophilic asthma in patients whose symptoms are not controlled by standard therapies.

This summary is based on a press release issued by GSK.